Cleveland, OH (PRWEB) August 14, 2014
With over 70,000 people suffering from cystic fibrosis (CF) worldwide, and 30,000 alone in the United States, the world is searching for impactful solutions to address the pain and suffering endured by people living with this debilitating disease.
To this end, ChanTest has announced a global campaign to share new findings and developments in CF research through the publication of a new, cutting-edge white paper entitled “Unfolding Cystic Fibrosis Research”. As a leader in supporting the drug discovery and development industry, ChanTest has played a crucial role in progressing our worldwide understanding on how to solve critical CF challenges.
Cystic fibrosis causes the creation of a thick and sticky mucus, which clogs important organs such as the lungs or the digestive system. CF is caused by a mutation in the gene for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Although there are over 1000 mutations that produce this disorder, the most common is the deletion of phenylalanine at position 508 of the CFTR protein (CFTR F508del). This results in the production of misfolded CFTR protein that is then rarely inserted into the cell membrane, where it belongs.
Nearly 90% of the CF population has at least one copy of the F508del mutation, which is why ChanTest focuses their research, and has produced this white paper, with an emphasis on ‘Unfolding’ cystic fibrosis.
The white paper not only focuses on the role of this important protein, but also discusses many scientific assay projects which have the potential to significantly affect those with cystic fibrosis. This testing and analysis, supported by assay work conducted by ChanTest, helps to show what methods, and therefore what drugs, are most effective in treating this disorder and its symptoms.
According to Dr. Anthony Lacerda, Director of Contract Research and Development at ChanTest, “Tools and methods such as the Ussing Chamber Assay from ChanTest allow us to be able to identify the best drug candidates that can have an effect on the cystic fibrosis protein: CFTR. This provides an unprecedented ability to significantly shorten our evaluation process, bringing us more quickly and cost efficiently to a real answer in our drug discovery and development support work.”
ChanTest’s goal is that their active participation in this research will further our collective efforts to aid in treating those with Cystic Fibrosis, as well as create a better understanding of the proteins at work in this disease.
ChanTest will have a major presence, and present their findings, at the 28th Annual Cystic Fibrosis Conference on October 9-11, 2014 in Atlanta, GA.
To learn more about ChanTest’s research in the area of CF, or to request a copy of “Unfolding Cystic Fibrosis Research”, visit http://www.chantest.com/news/white-papers.
About ChanTest® – The Ion Channel Expert
ChanTest’s mission is to serve the drug discovery and development needs of customers worldwide. Since its start in 1998, the Contract Research Organization has tested compounds for more than 300 global pharmaceutical and biotechnology companies. ChanTest also partners with these companies to accelerate the drug development process for the release of better, safer drugs. ChanTest offers ion channel and GPCR cell reagents, ion channel screening/profiling services, cardiac safety services and leading-edge work in cystic fibrosis assays. The company’s library of validated ion channel cell lines, and nonclinical cardiac risk assessment service portfolio, is the most comprehensive commercial library available today.
Because of ChanTest’s influential role in ion channel research, along with the company’s uncompromising commitment to quality, an independent survey has named ChanTest the “most trusted and most used fee-for-service provider” since 2006. ChanTest is based in Cleveland, Ohio.
Visit http://www.chantest.com to learn more about ChanTest.
14656 New Parkway
Cleveland, Ohio 44128
1-877-828-1777 Toll Free
Contact for Media Inquiries:
Chris Mathes, Ph.D., M.B.A.
Chief Commercial Officer
Read the full story at http://www.prweb.com/releases/2014/08/prweb12094221.htm.
Copyright©2014 Vocus, Inc.
All rights reserved